Part 2 – Hatch-Waxman and BPCIA Fundamentals: Understanding Follow-On Products and the Rules for Generic Entry

September 14, 2022 3:45pm

Bryan C. Diner
Partner
Finnegan, Henderson, Farabow, Garrett & Dunner LLP (Washington, DC)

Adam L. Perlman
Partner
Latham & Watkins LLP (Washington, DC)

Drugs
  • Overview of Hatch-Waxman and reforms
    • 30-month stay; patent extensions; ANDA filer exclusivity (180 day)
  • Comparing the NDA, 505(b)(2), and ANDA (Abbreviated New Drug Application) drug approval routes
    • Reviewing fundamentals of applications
  • Exploring the ANDA Paragraph IV Certification, and response to Notice Letters
  • Examining ANDA Standards for approval and the concepts of sameness and bioequivalence
  • Special considerations: local acting drugs, labeling carve outs and other nuances
    • Understanding the role of the Orange Book in the drug approval process
    • Listings, de-listings and use codes
  • Market exclusivities and protection
  • Identifying the different types of exclusivities
    • Regulatory exclusivity (FDA)/(data) exclusivity
      • NCE (new chemical entity)
    • 5 years data exclusivity
      • Indication (new indication or use)
    • 3 years marketing exclusivity
      • NDF (new dosage formulation)
      • ODE (orphan drug exclusivity)
      • PED (pediatric exclusivity)

Biologics
  • Overview of biosimilar legislation and regulations, i.e., Biologics Price Competition and Innovation Act of 2009 (BPCIA)
  • Understanding the rationale for safety and efficacy concerns surrounding second generation biologics
  • Exploring the concepts of “biosimilarity” or “interchangeability”
  • FDA rule-making and guidance relative to biosimilars
  • Other points for consideration: substitution, naming, patents, and additional nuances
  • Examining biosimilar exclusivities
  • “Shall we dance” — weighing the pros and cons of participating in the patent dance
  • Deciding when to provide notice of commercial marketing